BMS revises hepatitis B therapy warning label

Share this article:
The FDA reports that Bristol-Myers Squibb has revised hepatitis B therapy Baraclude's boxed warning labeling to caution against its use in HIV/hepatitis B virus co-infected patients who are not also receiving highly active antiretroviral therapy due to the potential for developing HIV resistance.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.